Table 1.

Study population characteristics

Author	Year	N	Median age	Baseline				Grade
				PSA ng/ml	PSA density ng/ml	PI-RADS distribution
Amin [22]	2020	100	64.5	4.7 (3.4–6.6)	0.11 (0.08–0.15)	0–2	51%	High
						3	36%
						4	12%
						5	1%
Chesnut [27]	2020	207	61	4.4 [3.6–5.5]	NR	0–2	40%	Moderate
						3	37%
						4	22%
						5	1%
Gallagher [24]	2019	150	65.3	6.8 [6.2–7.3]	0.11 (0.08–0.17)	0–2	NR	Moderate
						3	NR
						4	NR
						5	NR
Jayadevan [14]	2019	332	62.8*	4.7 [2.5–7.0]	0.08 (0.05–0.14)	0–2	31%	High
						3	42%
						4	22%
						5	5%
Nougaret [34]	2017	371	60	4.7 [0.05–9.97]	NR	0–2	NR	Moderate
						3	NR
						4	NR
						5	NR
Osses [26]	2020	111	66	6.8 [5.1–9.1]	0.17 (0.11–0.25)	0–2	47%	Moderate
						3	14%
						4	32%
						5	8%
Pepe [32]	2020	45	66	NR	NR	0–2	NR	Moderate
						3	NR
						4	NR
						5	NR
Kornberg [21]	2018	300	61.5*	NR	NR	0–2	24%	Moderate
						3	12%
						4	44%
						5	21%

Study population characteristics. All included studies enrolled patients with GG1 prostate cancer. Calculations regarding reclassification were performed when patients developed ≥ GG2 prostate cancer

*Mean age